<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447679</url>
  </required_header>
  <id_info>
    <org_study_id>CGMF-IRB-97-1291A</org_study_id>
    <nct_id>NCT02447679</nct_id>
  </id_info>
  <brief_title>Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence</brief_title>
  <official_title>Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-centered phase II clinical study is to obtain preliminary information on 1-year&#xD;
      recurrence-free survival rate, recurrence-free survival and safety profile of thalidomide in&#xD;
      combination with tegafur-uracil in hepatocellular carcinoma after hepatectomy and explore&#xD;
      biomarkers(VEGF/bFGF) for thalidomide response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After liver resection to remove the hepatocellular carcinioma completely, the patients with&#xD;
      high risk of tumor recurrence will be enrolled into this study. The high risk of tumor&#xD;
      recurrence depends on tumor characteristics. The risk factors of tumor characteristics&#xD;
      included tumor size &gt;5 cm in diameter, abscence of encapsulation, vascular invasion and&#xD;
      presence of daughter nodules. The patients with high risk of tumor recurrence will have 1 to&#xD;
      3 risk factors. When the patients are enrolled into the study, oral thalidomide in&#xD;
      combination with tegafur-uracil will be applied to prevent tumor recurrence. The patients&#xD;
      will be fillowed uo erevy 3 mnoths.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2, 2017</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor recurrence</measure>
    <time_frame>every 3 months, up to 5 years</time_frame>
    <description>Measure a-fetoprotein and perform liver echo to find out tumor recurrence every 3 month. Then, if a tumor/tumors are found in liver echo, tumor recurrence will be confirmed by CT scan. The imaging on CT shows typical HCC pattern.&#xD;
The pilot study is to obtain preliminary information on:&#xD;
3-year recurrence-free survival rate&#xD;
Recurrence-free survival&#xD;
Safety profile of the treatment&#xD;
Biomarkers response(VEGF/bFGF)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Adult Hepatocellular Carcinoma</condition>
  <condition>Recurrent Hepatocellular Carcinoma</condition>
  <condition>Adverse Reaction to Drug</condition>
  <condition>Vascular Endothelial Growth Factor Overexpression</condition>
  <arm_group>
    <arm_group_label>thalidomine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalidomide 400mg/day for 1 year&#xD;
tegafur-uracil 2 tables for 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomine</intervention_name>
    <description>thalidomine (400mg/day) for 1 year to prevent HCC recurrence</description>
    <arm_group_label>thalidomine</arm_group_label>
    <other_name>thado</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tegafur-uracil</intervention_name>
    <description>tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence</description>
    <arm_group_label>thalidomine</arm_group_label>
    <other_name>ufur</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. stage I-III（TNM: T1-T3） hepatocellular carcinoma&#xD;
&#xD;
          2. previously received curative surgery&#xD;
&#xD;
          3. presence at least one and no more than three of the following risk factors ,&#xD;
&#xD;
        i.Tumor size ≧ 5 cm ii.presence of microscopic or macrovascular venous invasion&#xD;
        iii.presence of satellite nodules/addition nodules iv.no capsular formation v.multiple&#xD;
        tumors d.performance status of ECOG 0, 1 e.age between 20 and 75 years f.no residual or&#xD;
        recurrent tumors detected by computed tomography (CT) or echo within 3-6 weeks after&#xD;
        surgery g.written informed consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. other malignancy with the exception of curative treated non-melanoma skin cancer or&#xD;
             cervical carcinoma in situ prior to the entry of study&#xD;
&#xD;
          2. previously received chemotherapy&#xD;
&#xD;
          3. less than 2 weeks since previous radiotherapy/surgery&#xD;
&#xD;
          4. white blood cell (WBC) less than 3,000/mm3 and absolute neutrophil count (ANC) less&#xD;
             than 1,500/mm3, and platelets less than 100,000/mm3&#xD;
&#xD;
          5. serum bilirubin greater than 1.5 times the upper limit of normal range (ULN)&#xD;
&#xD;
          6. alanine aminotransferase (ALT) or aspartate transaminase (AST) greater than 5 times&#xD;
             the ULN&#xD;
&#xD;
          7. alkaline phosphatase greater than 5 times the ULN&#xD;
&#xD;
          8. presence of serious concomitant illness which might be aggravated by study&#xD;
             medication:uncontrolled infection (active serious infections that are not controlled&#xD;
             by antibiotics)&#xD;
&#xD;
          9. hypersensitivity to thalidomide or compounds pregnant or breast feeding women, or&#xD;
             women of child-bearing potential unless using two reliable and appropriate&#xD;
             contraceptive method&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-Chen Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>February 5, 2017</last_update_submitted>
  <last_update_submitted_qc>February 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

